DDP-IV inhibitors improve insulin sensitivity and hepatic steatosis in animal models of diet-induced obesity with some evidence of improved liver inflammation [99] and may also limit progression to fibrosis in animal models of liver injury [100]. This evidence concerns the gene INS and fatty liver disease.